Cardiome shares battered after FDA places clinical hold on vernakalant Phase III trial

Shares of Cardiome Pharma sank 25% in premarket trading on 21 October after the company announced that an unexpected case of cardiogenic shock forced investigators at its partner, Astellas Pharma, to halt enrollment for a key Phase III confirmatory study of the atrial fibrillation drug vernakalant injection.